Galmed Pharmaceuticals Releases Annual Report for Fiscal Year 2025 Featuring Key Developments Galmed Pharmaceuticals has submitted its Annual Report for the fiscal year 2025, highlighting advancements in liver disease therapies and financial insights.

Galmed Pharmaceuticals Releases Annual Report for Fiscal Year 2025 Featuring Key Developments #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #Liver_Diseases

Galmed Pharmaceuticals to Present Late-Breaking Data at HEP-DART 2025 Meeting Galmed Pharmaceuticals announces a late-breaking abstract presentation at HEP-DART 2025, revealing new insights on their drug Aramchol's efficacy combined with regorafenib.

Galmed Pharmaceuticals to Present Late-Breaking Data at HEP-DART 2025 Meeting #Israel #Galmed_Pharmaceuticals #Aramchol #Regorafenib #Ramot_Gan

Galmed Pharmaceuticals Secures New Patent for Aramchol and Rezdiffra Combination Therapy Against MASH Galmed Pharmaceuticals announces a new patent for its Aramchol and Madrigal's Rezdiffra mixture to treat MASH, expanding its market position significantly.

Galmed Pharmaceuticals Secures New Patent for Aramchol and Rezdiffra Combination Therapy Against MASH #Israel #NASH #Aramchol #Galmed_pharmaceuticals #Ramat-Gan

Galmed Pharmaceuticals CEO Letter Highlights Growth and Future Prospects for Aramchol Galmed Pharmaceuticals' CEO Allen Baharaff discusses the company's recent achievements, financial stability, and future growth potential for Aramchol in various therapeutic areas.

Galmed Pharmaceuticals CEO Letter Highlights Growth and Future Prospects for Aramchol #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #Allen_Baharaff

Galmed Pharmaceuticals Updates on Third Quarter 2025 Financial Performance and Business Developments Galmed Pharmaceuticals has reported its financial results for Q3 2025, highlighting progress in clinical developments and financial growth in cash reserves.

Galmed Pharmaceuticals Updates on Third Quarter 2025 Financial Performance and Business Developments #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #VCU

Galmed Pharmaceuticals Unveils Promising Results for New Cancer Treatment Combining Aramchol, Stivarga® and Metformin Galmed Pharmaceuticals has reported significant success in combining Aramchol, Stivarga®, and Metformin for enhanced cancer treatment, promising new hope for patients.

Galmed Pharmaceuticals Unveils Promising Results for New Cancer Treatment Combining Aramchol, Stivarga® and Metformin #Israel #oncology #Ramat_Gan #Galmed_Pharmaceuticals #Aramchol

Galmed Pharmaceuticals Unveils New Biomarker Signature for Aramchol, Paving the Way for Major Market Expansion Galmed Pharmaceuticals has identified a new proprietary biomarker signature for Aramchol, significantly enhancing its expansion prospects in cardiometabolic markets alongside liver disease.

Galmed Pharmaceuticals Unveils New Biomarker Signature for Aramchol, Paving the Way for Major Market Expansion #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #Biomarker

Galmed Pharmaceuticals' First Quarter Results Showcase Financial Stability and Promising Research Developments Galmed Pharmaceuticals announced financial results for Q1 2025, highlighting growth in research and developments. With a solid cash balance and reduced net loss, Galmed is poised for future advancements.

Galmed Pharmaceuticals' First Quarter Results Showcase Financial Stability and Promising Research Developments #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #NASDAQ_GLMD

Galmed Pharmaceuticals Shows Aramchol's Promise Against Biliary Fibrosis In PSC Models Recent studies highlight Aramchol's ability to effectively reduce biliary fibrosis in mouse models of primary sclerosing cholangitis, paving the way for future clinical applications.

Galmed Pharmaceuticals Shows Aramchol's Promise Against Biliary Fibrosis In PSC Models #Israel #Tel_Aviv #PSC #Galmed_Pharmaceuticals #Aramchol

Galmed Pharmaceuticals Reports Promising Results with Aramchol and Regorafenib Combination in Cancer Studies Galmed Pharmaceuticals has announced significant findings on the effectiveness of Aramchol in boosting the effects of Bayer's Regorafenib against GI cancers, as reported by VCU's research.

Galmed Pharmaceuticals Reports Promising Results with Aramchol and Regorafenib Combination in Cancer Studies #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #Regorafenib

Galmed Pharmaceuticals Teams Up with VCU to Combat GI Cancer Drug Resistance Galmed Pharmaceuticals collaborates with Virginia Commonwealth University to study Aramchol's potential in overcoming drug resistance in GI cancers, creating hope for patients.

Galmed Pharmaceuticals Teams Up with VCU to Combat GI Cancer Drug Resistance #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #VCU

Galmed Pharmaceuticals Introduces Innovative Blood Markers for Aramchol, Leading SCD1 Inhibitor in Clinical Trials Galmed Pharmaceuticals presents new pharmacodynamic blood markers for Aramchol, enhancing understanding of its effects and potential in treating various diseases.

Galmed Pharmaceuticals Introduces Innovative Blood Markers for Aramchol, Leading SCD1 Inhibitor in Clinical Trials #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #Blood_Markers

Galmed Pharmaceuticals Achieves Significant Milestone with AM-001 Study of Aramchol Meglumine Galmed Pharmaceuticals has announced promising preliminary results from the AM-001 study, evaluating the effective Aramchol Meglumine formulation for NASH treatment.

Galmed Pharmaceuticals Achieves Significant Milestone with AM-001 Study of Aramchol Meglumine #Israel #Tel_Aviv #NASH #Aramchol #Galmed

Galmed Pharmaceuticals' Comprehensive Annual Report: Key Insights and Future Directions Galmed Pharmaceuticals has released its Annual Report on Form 20-F for the fiscal year ending December 31, 2024, outlining significant developments and future strategies.

Galmed Pharmaceuticals' Comprehensive Annual Report: Key Insights and Future Directions #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #NASDAQ_GLMD

Galmed Pharmaceuticals Extends Aramchol's Patent Protection to 2039 for NASH Therapy Enhancement Galmed Pharmaceuticals has secured a new patent for Aramchol, extending its protection to 2039. This move enhances its position in the NASH treatment landscape and supports the development of combination therapies.

Galmed Pharmaceuticals Extends Aramchol's Patent Protection to 2039 for NASH Therapy Enhancement #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #NASH_Therapy

@HepDART dr. Martins @Allergan summarizes ph3 trials planned in progress #obeticholicacid #cenicriviroc #aramchol #resmetirom #elafibranor #belapectin #galectin #hepdart